title: Vilanterol trifenatate for the treatment of COPD.
abstract: Currently the treatment of chronic obstructive pulmonary disease (COPD) has limited effectiveness and there is a need to develop new drugs. International guidelines recommend the use of long-acting bronchodilators (β2 agonists and anti-cholinergics/muscarinics), inhaled steroids and associations between these drugs in the maintenance treatment of moderate-to-severe COPD.
  
  
  
  Vilanterol trifenate is a new once-daily highly selective β2-agonist available in USA and Europe in association with umeclidinium bromide (a long-acting anti-muscarnic agent) and fluticasone furoate (an inhaled corticosteroid) for the once-daily maintenance treatment of COPD. Vilanterol combined in fixed-dose treatments has been tested in numerous clinical trials involving thousands of patients. Expert commentary: These new once-daily formulations have the potential to improve compliance to long-term inhaled therapy. This paper will review the clinical and experimental data regarding vilanterol use in the regular treatment of COPD as well as provide a critical discussion of possible future treatment settings.
authors.affiliation: a Department of Internal Medicine , University of Brescia and ASST Spedali Civili , Brescia , Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Malerba
authors.affiliation: b Department of Emergency , ASST Spedali Civili , Brescia , Italy.
authors.forename: Alessandro
authors.initials: A
authors.lastname: Radaeli
authors.affiliation: c Department of Pharmacology, Faculty of Medicine , University Hospital Agostino Gemelli, Catholic University of the Sacred Heart , Rome , Italy.
authors.forename: Paolo
authors.initials: P
authors.lastname: Montuschi
authors.affiliation: d Department of Respiratory Medicine , Royal Brompton & Harefield NHS Trust, Harefield Hospital , Middlesex , UK.
authors.forename: Jaymin B
authors.initials: JB
authors.lastname: Morjaria
mesh_terms: D001592:Benzyl Alcohols / Q000494:pharmacology* / Q000627:therapeutic use; D002722:Chlorobenzenes / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D001592:Benzyl Alcohols; D002722:Chlorobenzenes; C550468:vilanterol
keywords: COPD treatment; LABA; LAMA; Vilanterol trifenate; fluticasone furoate; umeclidinium bromide